缬沙坦联合卡维地洛在慢性心力衰竭治疗中的临床研究

目的探讨缬沙坦联合卡维地洛在治疗慢性心力衰竭中的临床疗效及安全性,为临床治疗提供参考。方法回顾性分析于2010年3月～2011年3月收治入院的60例慢性心力衰竭患者随机分为治疗组(缬沙坦联合卡维地洛)和对照组(常规治疗)。疗程为6个月。对照组用强心苷及利尿药常规治疗,治疗组在常规治疗基础上加用缬沙坦及卡维地洛。比较治疗前后左室射血分数、心功能等。结果两组治疗半年后,对照组为73.3%,治疗组总有效率为96.7%,(P<0.05),心功能改善明显。结论缬沙坦和卡维地洛联合治疗可提高疗效,明显改善心衰患者的预后,减轻病人痛苦,可在临床治疗中积极推广。

Objective To investigate valsartan combined carvedilol in the treatment of chronic heart failure in the clinical efficacy and safety, provide a reference for clinical treatment. Methods A retrospective analysis of our hospital in March 2010 to March 2011 admitted to hospital, 60 patients with chronic heart failure were randomly divided into treatment groups （valsartan combined carvedilol） and the control group （conventional treatment）. Treatment for 6 months. The control group of cardiac glycosides and diuretics conventional treatment group on the basis of conventional therapy plus valsartan and carvedilol. Left ventricular ejection fi^action before and after treatment, heart function. Results After treatment, six months after the control group was 73.3%, total effective rate was 96.7%, （P〈0.05）, heart function improved significantly. Conclusion Valsartan and carvedilol can improve the efficacy of combination therapy, significantly improved the prognosis of patients with heart failure, reduce patient suffering, in the clinical treatment of active promotion.